ARQT - Arcutis Biotherapeutics, Inc.

QQQ $ 451.63 $ -0.22 (-0.05 %)

DIA $ 399.76 $ 0.74 (0.19 %)

SPY $ 529.24 $ 0.76 (0.14 %)

TLT $ 91.40 $ -0.62 (-0.67 %)

GLD $ 223.63 $ 3.63 (1.65 %)

Previous Close

$ 9.2

Open

$ 9.02

Bid

$ 0.00 x 0

Ask

$ 0.00 x 0

Day's Range

$ 8.52 - $ 9.30

52 Week Range

$ 1.76 - $ 13.17

Volume

3,448,901

Average Volume

Market Cap

1.02B

Beta (5Y Monthly)

$ 0.42

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	05-14-2024	03-31-2024	10-Q
2	02-27-2024	12-31-2023	10-K
3	11-03-2023	09-30-2023	10-Q
4	08-08-2023	06-30-2023	10-Q
5	05-09-2023	03-31-2023	10-Q
6	02-28-2023	12-31-2022	10-K
7	11-08-2022	09-30-2022	10-Q
8	08-04-2022	06-30-2022	10-Q
9	05-05-2022	03-31-2022	10-Q
10	02-22-2022	12-31-2021	10-K
11	11-04-2021	09-30-2021	10-Q
12	08-05-2021	06-30-2021	10-Q
13	05-06-2021	03-31-2021	10-Q
14	02-16-2021	12-31-2020	10-K
15	11-05-2020	09-30-2020	10-Q
16	08-11-2020	06-30-2020	10-Q
17	05-12-2020	03-31-2020	10-Q
18	03-19-2020	12-31-2019	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

why-bolt-biotherapeutics-shares-are-trading-lower-by-around-34-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why Bolt Biotherapeutics Shares Are Tradin...
05/15/2024 17:38:38

Needham Maintains Buy on Arcutis Biotherap...
05/15/2024 15:51:18

Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $...

nextracker-posts-upbeat-earnings-joins-mondaycom-nu-holdings-and-other-big-stocks-moving-higher-on-wednesday

NEXTracker Posts Upbeat Earnings, Joins mo...
05/15/2024 14:21:59

Market-Moving News for May 15th
05/15/2024 12:33:09

EDBL: 87% | Edible Garden shares are trading higher. The company reported Q1 financial results. MNDY: 22% | Monday.com shares ...

why-arcutis-biotherapeutics-shares-are-trading-higher-by-29-here-are-20-stocks-moving-premarket

Why Arcutis Biotherapeutics Shares Are Tra...
05/15/2024 12:14:56

12-health-care-stocks-moving-in-wednesdays-pre-market-session

12 Health Care Stocks Moving In Wednesday'...
05/15/2024 12:06:56

Mizuho Maintains Buy on Arcutis Biotherape...
05/15/2024 11:09:02

Mizuho analyst Uy Ear maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $17 to $18.

arcutis-biotherapeutics-stock-climbs-after-blockbuster-q1-results

Arcutis Biotherapeutics Stock Climbs After...
05/14/2024 21:11:26

Arcutis Biotherapeutics reports its first-quarter financial results after the bell Tuesday.

12-health-care-stocks-moving-in-tuesdays-after-market-session

12 Health Care Stocks Moving In Tuesday's ...
05/14/2024 20:31:13

Arcutis Biotherapeutics Q1 2024 Adj EPS $0...
05/14/2024 20:02:30

Arcutis Biotherapeutics (NASDAQ:ARQT) reported quarterly earnings of $0.32 per share which beat the analyst consensus estimate ...

The Journal Of Clinical And Aesthetic Derm...
05/13/2024 12:08:22

Eight of nine experts expressed feeling "extremely confident" about prescribing ZORYVE foam to patients of diverse skin...

Evaluating Arcutis Biotherapeutics: Insigh...
04/12/2024 12:00:53

Needham Reiterates Buy on Arcutis Biothera...
04/12/2024 10:44:55

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $16 price target.

Arcutis Appoints David Topper As Chief Fin...
04/10/2024 12:05:37

eqt-genie-energy-and-other-big-stocks-moving-lower-on-monday

EQT, Genie Energy And Other Big Stocks Mov...
03/11/2024 14:37:32

U.S. stocks were lower, with the Dow Jones index falling more than 150 points on Monday.

Sunday, Arcutis Biotherapeutics' New Data ...
03/11/2024 09:11:57

Arcutis Announces Acceptance Of Late Break...
03/04/2024 13:18:25

Late breaking sessions to highlight new data from the INTEGUMENT-PED trial evaluating roflumilast cream 0.05% in children ages ...

Arcutis Prices $150M Public Offering Of 15...
02/29/2024 08:00:02

The gross proceeds to Arcutis from the offering are expected to be approximately $150.0 million, before deducting underwriting ...

Arcutis And Sato Announce Strategic Collab...
02/28/2024 21:03:19

Arcutis to receive a $25 million upfront payment, and is eligible to receive potential development and commercial milestone pay...

Goldman Sachs Maintains Neutral on Arcutis...
02/28/2024 16:21:20

Goldman Sachs analyst Jonathan Block maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Neutral and raises the price tar...